CY1122168T1 - Φαρμακοτεχνικες μορφες παραγωγων δεσιταβινης - Google Patents

Φαρμακοτεχνικες μορφες παραγωγων δεσιταβινης

Info

Publication number
CY1122168T1
CY1122168T1 CY20181101369T CY181101369T CY1122168T1 CY 1122168 T1 CY1122168 T1 CY 1122168T1 CY 20181101369 T CY20181101369 T CY 20181101369T CY 181101369 T CY181101369 T CY 181101369T CY 1122168 T1 CY1122168 T1 CY 1122168T1
Authority
CY
Cyprus
Prior art keywords
derivatives
pharmaceutical forms
decitabine
decitabine derivatives
leukemia
Prior art date
Application number
CY20181101369T
Other languages
English (en)
Inventor
Rajashree Joshi-Hangal
Chunlin Tang
Sanjeev Redkar
Harish Ravivarapu
Original Assignee
Astex Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astex Pharmaceuticals, Inc. filed Critical Astex Pharmaceuticals, Inc.
Publication of CY1122168T1 publication Critical patent/CY1122168T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Abstract

Η εφεύρεση παρέχει παράγωγα δεσιταβίνης με ανώτερη χημική σταθερότητα και διάρκεια ζωής στο ράφι, με παρόμοια φυσιολογική δραστικότητα. Τα παράγωγα παρέχονται σε μια μη-υδατική φαρμακοτεχνική μορφή, η οποία περαιτέρω σταθεροποιεί τα παράγωγα. Περιγράφονται μέθοδοι θεραπείας ενός ή περισσοτέρων μυελοδυσπλαστικών συνδρόμων, λευχαιμίας, ή συμπαγών όγκων χρησιμοποιώντας τις φαρμακοτεχνικές μορφές.
CY20181101369T 2011-08-30 2018-12-19 Φαρμακοτεχνικες μορφες παραγωγων δεσιταβινης CY1122168T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161529081P 2011-08-30 2011-08-30
PCT/US2012/052816 WO2013033176A1 (en) 2011-08-30 2012-08-29 Decitabine derivative formulations

Publications (1)

Publication Number Publication Date
CY1122168T1 true CY1122168T1 (el) 2020-07-31

Family

ID=46875963

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20181101369T CY1122168T1 (el) 2011-08-30 2018-12-19 Φαρμακοτεχνικες μορφες παραγωγων δεσιταβινης

Country Status (26)

Country Link
US (4) US9381207B2 (el)
EP (2) EP3431142B1 (el)
JP (2) JP6038921B2 (el)
KR (1) KR102004559B1 (el)
CN (2) CN103945902B (el)
AU (2) AU2012302051B2 (el)
BR (1) BR112014004779B1 (el)
CA (1) CA2845585C (el)
CO (1) CO6950470A2 (el)
CY (1) CY1122168T1 (el)
DK (1) DK2750768T3 (el)
ES (1) ES2702495T3 (el)
HK (1) HK1199715A1 (el)
HU (1) HUE042327T2 (el)
IL (2) IL231209A0 (el)
LT (1) LT2750768T (el)
MX (1) MX359314B (el)
MY (2) MY186676A (el)
PH (1) PH12018501678A1 (el)
PL (1) PL2750768T3 (el)
PT (1) PT2750768T (el)
RU (1) RU2605289C2 (el)
SG (1) SG2014013395A (el)
UA (1) UA116528C2 (el)
WO (1) WO2013033176A1 (el)
ZA (1) ZA201701083B (el)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7700567B2 (en) 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
US10166142B2 (en) 2010-01-29 2019-01-01 Forsight Vision4, Inc. Small molecule delivery with implantable therapeutic device
CA2818612C (en) 2010-11-19 2020-12-29 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
ES2702495T3 (es) 2011-08-30 2019-03-01 Astex Pharmaceuticals Inc Formulaciones de derivados de decitabina
PL2961388T3 (pl) * 2013-03-01 2019-10-31 Astex Pharmaceuticals Inc Kombinacje lekowe
US9968603B2 (en) 2013-03-14 2018-05-15 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
CN107106551A (zh) * 2014-08-08 2017-08-29 弗赛特影像4股份有限公司 受体酪氨酸激酶抑制剂的稳定且可溶的制剂和其制备方法
CN108024535A (zh) * 2015-07-02 2018-05-11 大塚制药株式会社 冻干药物组合物
GB201704966D0 (en) 2017-03-28 2017-05-10 Astex Therapeutics Ltd Pharmaceutical compounds
GB201704965D0 (en) 2017-03-28 2017-05-10 Astex Therapeutics Ltd Pharmaceutical compounds
EP3661522A2 (en) 2017-08-03 2020-06-10 Otsuka Pharmaceutical Co., Ltd. Drug compound and purification methods thereof
CA3211506A1 (en) * 2018-02-07 2019-08-15 Lovelace Biomedical Research Institute Inhalable dry powder cytidine analogue composition and method of use as a treatment for cancer
KR20220083704A (ko) * 2019-10-18 2022-06-20 후지필름 와코 준야쿠 가부시키가이샤 포스포아미다이트 활성화제
US20220096507A1 (en) * 2020-07-01 2022-03-31 Sandoz Ag Parenteral Pharmaceutical Composition Comprising Azacitidine or Decitabine in DMSO

Family Cites Families (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3133858A (en) * 1954-03-24 1964-05-19 Abbott Lab Stable thiobarbituric acid solution
CH527207A (de) 1968-05-08 1972-08-31 Ceskoslovenska Akademie Ved Verfahren zur Herstellung von 1-Glycosyl-5-azacytosinen
DE2105468A1 (en) 1970-04-23 1971-11-18 Czeskoslovenska akademie ved, Prag; VtnKarstedt, E., Dipl.-Ing. Dr., Pat-Anw., 4200 Oberhausen 1-glycosyl-5-aza-cytosines prepn
US5157120A (en) 1980-09-16 1992-10-20 Syntex (U.S.A.) Inc. Guanine derivatives
US4855304A (en) 1985-01-10 1989-08-08 Repligen Corporation Dinucleoside pyrophosphates and pyrophosphate homologs as plant antivirals
JPS61176523A (ja) 1985-01-30 1986-08-08 Teruhiko Beppu 制癌剤
GB8612826D0 (en) 1986-05-27 1986-07-02 Boots Co Plc Insecticidal compositions
DE3712786A1 (de) 1987-04-15 1988-11-03 Merck Patent Gmbh Verfahren und mittel zur bestimmung von nucleinsaeuren
CS269077B1 (cs) 1987-10-01 1990-04-11 Piskala Alois Způsob přípravy 5-azacytosinů
US5736531A (en) 1987-10-28 1998-04-07 Pro-Neuron, Inc. Compositions of chemotherapeutic agent or antiviral agent with acylated pyrimidine nucleosides
US5968914A (en) 1987-10-28 1999-10-19 Pro-Neuron, Inc. Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
US4904770A (en) 1988-03-24 1990-02-27 Bristol-Myers Company Production of 2',3'-dideoxy-2',3'-didehydronucleosides
US5324831A (en) 1988-04-06 1994-06-28 The United States Of America As Represented By The Secretary Of Health And Human Services Phosphoramidite reagent for chemical synthesis of modified DNA
PT93772A (pt) 1989-04-17 1991-01-08 Searle & Co Processo para a preparacao de composicoes para o tratamento de neoplasias, contendo um agente anti-neoplastico, por exemplo doxorubicina e um agente protector para reduzir os efeitos secundarios, por exemplo carbetimer
ZA923641B (en) 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
AU667676B2 (en) 1991-07-05 1996-04-04 Pro-Neuron, Inc. Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
IL103311A0 (en) 1991-10-07 1993-03-15 Univ Johns Hopkins Formation of triple helix complexes of single stranded nucleic acids using nucleoside oligomers
JPH05219974A (ja) 1992-02-13 1993-08-31 Mitsui Petrochem Ind Ltd トロパンアルカロイドの製造方法
JPH05246891A (ja) * 1992-03-09 1993-09-24 Kobayashi Seiyaku Kogyo Kk 安定な抗膵炎用注射液
US5607691A (en) 1992-06-12 1997-03-04 Affymax Technologies N.V. Compositions and methods for enhanced drug delivery
AU6081294A (en) 1993-05-14 1994-12-12 Pro-Neuron, Inc. Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
GB9311252D0 (en) 1993-06-01 1993-07-21 Hafslund Nycomed As Cell growth regualtors
US6184211B1 (en) 1993-11-30 2001-02-06 Methylgene Inc. Inhibition of DNA methyltransferase
US6432924B1 (en) 1993-12-26 2002-08-13 East Carolina University Method of treating disorders characterized by overexpression of cytidine deaminase or deoxycytidine deaminase
US5856090A (en) 1994-09-09 1999-01-05 The Scripps Research Institute DNA-methylase linking reaction
US20030104576A1 (en) 1994-10-07 2003-06-05 Jonathan W. Nyce Dna construct, composition, formulations & methods for making the construct & for modulating expression
EP0871707A4 (en) 1995-05-19 2000-10-25 Phytera Inc MANIPULATION OF VEGETABLE CELL AND TISSUE CULTURES
EP0852463B1 (en) 1995-06-06 2008-09-03 Case Western Reserve University Myogenic differentiation of human mesenchymal stem cells
WO1997023230A1 (en) 1995-12-22 1997-07-03 East Carolina University Method of treating disorders characterized by overexpression of cytidine deaminase or deoxycytidine deaminase
UA63915C2 (uk) 1996-10-16 2004-02-16 Ай-Сі-Ен Фармасьютикалз, Інк. МОНОЦИКЛІЧНИЙ L-НУКЛЕОЗИД, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, СПОСІБ ЛІКУВАННЯ ТА СПОСІБ ІНВЕРСІЙНОГО МОДУЛЮВАННЯ АКТИВНОСТІ Th1 ТА Th2
US6423692B2 (en) 1997-04-24 2002-07-23 Dana-Farber Cancer Institute, Inc. Method of enhancing the effectiveness of DCK phosphorylated molecules
US6153383A (en) 1997-12-09 2000-11-28 Verdine; Gregory L. Synthetic transcriptional modulators and uses thereof
KR100633212B1 (ko) 1998-02-05 2006-10-11 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신접종을 위한 융합 단백질 및 조성물의 제조를 위해사용되는 ｍａｇｅ 군으로부터의 종양 관련 항원 유도체및 이들을 암호화하고 있는 핵산 서열
CA2347003A1 (en) 1998-10-19 2000-04-27 Methylgene, Inc. Modulation of gene expression by combination therapy
HU229566B1 (en) 1998-12-23 2014-02-28 Pfizer Human monoclonal antibodies to ctla-4
WO2000040269A2 (en) 1999-01-05 2000-07-13 Lee Clarence C Pharmaceutical compositions for treatment of diseased tissues
WO2000062075A1 (en) 1999-04-13 2000-10-19 Rutgers, The State University Of New Jersey Ubiquitin cross-reactive protein as a prognostic marker for tumor cell chemosensitivity
WO2000074634A2 (en) 1999-06-03 2000-12-14 Au Jessie L S Methods and compositions for modulating cell proliferation and cell death
DE19935303A1 (de) 1999-07-28 2001-02-08 Aventis Pharma Gmbh Oligonukleotide zur Inhibierung der Expression von humanem eg5
CN1371416B (zh) 1999-08-24 2012-10-10 梅达里克斯公司 人ctla-4抗体及其应用
JP2001163776A (ja) * 1999-09-30 2001-06-19 Nisshin Oil Mills Ltd:The 安定化された液剤
AU785115B2 (en) 1999-10-18 2006-09-21 Emory University TMS1 compositions and methods of use
US20020115117A1 (en) 2000-03-15 2002-08-22 Shuk-Mei Ho ERbeta-mediated gene expression
CN1460181A (zh) 2000-09-08 2003-12-03 汉城国立大学工业基金会 参与细胞衰老的核酸序列和蛋白质
WO2002043765A2 (en) * 2000-11-28 2002-06-06 Transform Pharmaceuticals, Inc. Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof
WO2002053138A2 (en) 2001-01-02 2002-07-11 Elisabeth Shanahan-Prendergast Treatment for inhibiting neoplastic lesions using incensole and/or furanogermacrens
SI1355916T1 (sl) 2001-01-22 2007-04-30 Merck & Co Inc Nukleozidni derivati kot inhibitorji RNA-odvisne RNA virusne polimeraze
JP2002223753A (ja) 2001-01-30 2002-08-13 Hitachi Ltd 薬物応答解析用オリゴヌクレオチドアレイ
JP2004527242A (ja) 2001-02-05 2004-09-09 イノベンタス プロジェクト アクチボラゲット ヒスチジンリッチ糖タンパク質
US6613753B2 (en) 2001-02-21 2003-09-02 Supergen, Inc. Restore cancer-suppressing functions to neoplastic cells through DNA hypomethylation
WO2002069903A2 (en) 2001-03-06 2002-09-12 Biocryst Pharmaceuticals, Inc. Nucleosides, preparation thereof and use as inhibitors of rna viral polymerases
US20060194275A1 (en) 2001-04-13 2006-08-31 Incyte Corporation Transporter and ion channels
US6905669B2 (en) 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
NZ528994A (en) 2001-04-26 2006-02-24 Control Delivery Sys Inc Sustained release drug delivery system containing codrugs
US20030148973A1 (en) 2001-05-23 2003-08-07 Peter Emtage MAGE-A1 peptides for treating or preventing cancer
AU2002318336A1 (en) 2001-06-08 2002-12-23 U.S. Genomics, Inc. Methods and products for analyzing nucleic acids based on methylation status
JP2002370939A (ja) 2001-06-12 2002-12-24 Taisho Pharmaceut Co Ltd 育毛剤
SE518759C2 (sv) 2001-07-27 2002-11-19 Geneinvent Bbl Ab Vektorer motståndskraftiga mot metylering
US20030045497A1 (en) 2001-07-27 2003-03-06 Geneinvent Bbl Ab Methylation resistant vectors
WO2003012085A1 (en) 2001-07-30 2003-02-13 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Antigen presenting cells, method for their preparation and their use for cancer vaccines
DK2177223T3 (da) 2001-09-05 2012-04-10 Chemgenex Pharmaceuticals Ltd Homoharringtonin alene eller kombineret med andre midler til anvendelse i behandling af kronisk myeloid leukæmi der er resistent eller intolerent over for proteinkinaseinhibitorer andre end STI 571
US20030158598A1 (en) 2001-09-17 2003-08-21 Control Delivery Systems, Inc. System for sustained-release delivery of anti-inflammatory agents from a coated medical device
IN2014DN10834A (el) 2001-09-17 2015-09-04 Psivida Inc
KR20040062546A (ko) 2001-09-24 2004-07-07 제시 엘. 에스. 에이유 병용 요법에 이용되는 수라민의 약제감작화 용량을결정하는 방법 및 조성물
US7432050B2 (en) 2001-10-05 2008-10-07 Case Western Reserve University Methods and compositions for detecting colon cancers
US7132587B2 (en) 2001-11-08 2006-11-07 Agency Of Industrial Science And Technology Non-autonomous transposon gene of rice, transformed plant and method of use
IL161785A0 (en) 2001-11-23 2005-11-20 Chugai Pharmaceutical Co Ltd Method for identification of tumor targeting enzymes
DE60234115D1 (de) 2001-11-29 2009-12-03 Dandrit Biotech As Pharmazeutische zusammensetzung zur auslösung einer immunantwort bei einem menschen oder einem tier
WO2003046190A1 (de) 2001-11-30 2003-06-05 Medigene Aktiengesellschaft Optimierte herstellung von viralen, von parvoviren abgeleiteten vektoren in verpackungs- und produktionszellen durch hsv-infektion oder behandlung mit inhibitoren der dna-methylierung
GB0201498D0 (en) 2002-01-23 2002-03-13 Biotech Res Ventures Pte Ltd Materials and methods for treating cancer
US20030147813A1 (en) 2002-02-07 2003-08-07 John Lyons Method for treating chronic myelogenous leukemia
US6998391B2 (en) 2002-02-07 2006-02-14 Supergen.Inc. Method for treating diseases associated with abnormal kinase activity
WO2003076660A1 (en) 2002-03-13 2003-09-18 F.Hoffmann-La Roche Ag Method for selecting drug sensitivity-determining factors and method for predicting drug sensitivity using the selected factors
JP2003310293A (ja) 2002-04-26 2003-11-05 Mitsui Chemicals Inc ヌクレオシド化合物の製造法
AU2003231293A1 (en) 2002-05-02 2003-11-17 Wyeth Holdings Corporation Calicheamicin derivative-carrier conjugates
US6982253B2 (en) 2002-06-05 2006-01-03 Supergen, Inc. Liquid formulation of decitabine and use of the same
WO2003104427A2 (en) 2002-06-05 2003-12-18 Case Western Reserve University Methods and compositions for detecting cancers
US20040162263A1 (en) 2002-10-31 2004-08-19 Supergen, Inc., A Delaware Corporation Pharmaceutical formulations targeting specific regions of the gastrointesinal tract
US20050037992A1 (en) 2003-07-22 2005-02-17 John Lyons Composition and method for treating neurological disorders
US20050059682A1 (en) 2003-09-12 2005-03-17 Supergen, Inc., A Delaware Corporation Compositions and methods for treatment of cancer
WO2005033278A2 (en) 2003-09-30 2005-04-14 Ludwig Institute For Cancer Research In vivo efficacy of ny-eso-1 plus iscom
US7846436B2 (en) 2003-11-28 2010-12-07 Chemgenes Corporation Oligonucleotides and related compounds
WO2005115450A1 (en) 2004-05-26 2005-12-08 Biovaxim Limited Compositions comprising demethylating agents as enhancers of immunotherapy for the treatment of chronic infections and neoplastic diseases and methods for treating the same
US20060014949A1 (en) 2004-07-13 2006-01-19 Supergen Inc. Compositions and formulations of decitabine polymorphs and methods of use thereof
US20060069060A1 (en) 2004-09-27 2006-03-30 Sanjeev Redkar Salts of decitabine
US20060063735A1 (en) 2004-09-17 2006-03-23 Supergen, Inc. Salts of 5-azacytidine
CA2586844A1 (en) 2004-11-04 2006-05-11 Pfizer Products Inc. Ctla-4 antibody and aromatase inhibitor or combination treatment for breast cancer
US20060128654A1 (en) 2004-12-10 2006-06-15 Chunlin Tang Pharmaceutical formulation of cytidine analogs and derivatives
US20060128653A1 (en) 2004-12-10 2006-06-15 Chunlin Tang Pharmaceutical formulation of decitabine
JP2008526760A (ja) 2004-12-29 2008-07-24 マンカインド コーポレイション 種々の腫瘍関連抗原を含む組成物の抗癌ワクチンとしての使用
US7250416B2 (en) 2005-03-11 2007-07-31 Supergen, Inc. Azacytosine analogs and derivatives
JO2787B1 (en) * 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
KR101498834B1 (ko) 2005-05-09 2015-03-05 오노 야꾸힝 고교 가부시키가이샤 예정 사멸 인자 1(ｐｄ-1)에 대한 인간 모노클로날 항체, 및 항-ｐｄ-1 항체를 단독 사용하거나 기타 면역 요법제와 병용한 암 치료 방법
HUE026039T2 (en) 2005-07-01 2016-05-30 Squibb & Sons Llc Human monoclonal antibodies programmed for death ligand 1 (PD-L1)
US7700567B2 (en) 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
US20070117776A1 (en) 2005-11-04 2007-05-24 John Lyons Low Dose Therapy Of DNA Methylation Inhibitors
US20070105792A1 (en) 2005-11-04 2007-05-10 Dimartino Jorge F Administration Of DNA Methylation Inhibitors For Treating Epigenetic Diseases
CN101637444B (zh) * 2006-03-17 2012-08-15 山东蓝金生物工程有限公司 含吉西他滨的抗癌药物缓释注射剂
EP2026805A1 (en) * 2006-05-08 2009-02-25 Astex Therapeutics Limited Pharmaceutical combinations of diazole derivatives for cancer treatment
WO2009051827A1 (en) * 2007-10-18 2009-04-23 The United States Of America As Represented By The Department Of Veterans Affairs Modulation of sodium channels by nicotinamide adenine dinucleotide
CN101570553B (zh) * 2008-05-04 2012-03-28 上海医药工业研究院 一种2-脱氧-d-核糖的衍生物及其制备方法和用途
CN101361718B (zh) * 2008-09-26 2013-08-28 深圳万乐药业有限公司 稳定的地西他滨冻干制剂的制备方法
CN101787046B (zh) * 2010-02-11 2012-12-26 福建南方制药股份有限公司 地西他滨的中间体化合物的制备方法
GB201006096D0 (en) 2010-04-13 2010-05-26 Alligator Bioscience Ab Novel compositions and uses thereof
KR20130096731A (ko) 2010-09-08 2013-08-30 할로자임, 아이엔씨 조건부 활성 치료적 단백질을 평가，확인 또는 진화시키는 방법
CN101966157B (zh) * 2010-10-14 2013-08-14 苏州特瑞药业有限公司 一种地西他滨缓释微球及其制备方法
AU2012241373B2 (en) 2011-04-15 2016-06-09 Compugen Ltd. Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer
ES2702495T3 (es) 2011-08-30 2019-03-01 Astex Pharmaceuticals Inc Formulaciones de derivados de decitabina
WO2013117969A1 (en) 2012-02-06 2013-08-15 Fresenius Kabi Oncology Ltd. Process for preparing stable pharmaceutical compositions of compounds susceptible to hydrolysis
PL2961388T3 (pl) 2013-03-01 2019-10-31 Astex Pharmaceuticals Inc Kombinacje lekowe
CN108024535A (zh) 2015-07-02 2018-05-11 大塚制药株式会社 冻干药物组合物
EP3661522A2 (en) 2017-08-03 2020-06-10 Otsuka Pharmaceutical Co., Ltd. Drug compound and purification methods thereof

Also Published As

Publication number Publication date
EP3431142A1 (en) 2019-01-23
BR112014004779B1 (pt) 2022-01-18
MY186676A (en) 2021-08-05
US20140303107A1 (en) 2014-10-09
US9913856B2 (en) 2018-03-13
RU2014112108A (ru) 2015-10-10
EP3431142B1 (en) 2020-06-17
US20200155588A1 (en) 2020-05-21
SG2014013395A (en) 2014-05-29
ES2702495T3 (es) 2019-03-01
CA2845585A1 (en) 2013-03-07
PL2750768T3 (pl) 2019-05-31
IL231209A0 (en) 2014-04-30
CA2845585C (en) 2020-02-18
AU2017204536A1 (en) 2017-07-20
US20160346310A1 (en) 2016-12-01
JP6038921B2 (ja) 2016-12-07
CN108635367A (zh) 2018-10-12
EP2750768B1 (en) 2018-10-03
MX2014002433A (es) 2014-10-13
US20180369267A1 (en) 2018-12-27
CN103945902A (zh) 2014-07-23
AU2012302051A1 (en) 2014-04-17
PH12018501678A1 (en) 2019-09-16
JP2017052775A (ja) 2017-03-16
UA116528C2 (uk) 2018-04-10
HK1199715A1 (en) 2015-07-17
KR20150000451A (ko) 2015-01-02
EP2750768A1 (en) 2014-07-09
AU2012302051B2 (en) 2017-04-27
CO6950470A2 (es) 2014-05-20
US10517886B2 (en) 2019-12-31
BR112014004779A2 (pt) 2018-08-14
JP2014525449A (ja) 2014-09-29
MY163296A (en) 2017-09-15
CN108635367B (zh) 2020-08-21
AU2017204536B2 (en) 2018-12-06
CN103945902B (zh) 2018-07-20
WO2013033176A1 (en) 2013-03-07
IL261562A (en) 2018-10-31
DK2750768T3 (en) 2019-01-21
MX359314B (es) 2018-09-25
NZ621322A (en) 2016-07-29
US11058705B2 (en) 2021-07-13
RU2605289C2 (ru) 2016-12-20
PT2750768T (pt) 2018-12-19
LT2750768T (lt) 2019-02-11
ZA201701083B (en) 2020-05-27
KR102004559B1 (ko) 2019-07-26
US9381207B2 (en) 2016-07-05
JP6257734B2 (ja) 2018-01-10
HUE042327T2 (hu) 2019-06-28

Similar Documents

Publication Publication Date Title
CY1122168T1 (el) Φαρμακοτεχνικες μορφες παραγωγων δεσιταβινης
CY1122554T1 (el) Συνδυασμοι φαρμακων
CY1124446T1 (el) Μορφες δοσολογιας της ρουξολιτινιμπης παρατεταμενης αποδεσμευσης
CY1123407T1 (el) Σταθερες υδατικες φαρμακοτεχνικες μορφες της αδαλιμουμαμπης
CY1120318T1 (el) Υποκατεστημενες βενζυλινδαζολες για χρηση ως αναστολεις κινασης bub1 στη θεραπευτικη αντιμετωπιση υπερπολλαπλασιαστικων ασθενειων
CY1124407T1 (el) Ενωσεις αναστολεα αυτοταξινης
CY1118695T1 (el) Αναστολεις απομεθυλασων ιστονων
CY1121882T1 (el) Αναστολεις πυραζολυλο κινοξαλινο κινασης
CY1123626T1 (el) Ετεροκυκλικοι αναστολεις πρωτεϊνικης κινασης
CY1122730T1 (el) 1,2,4-τριαζολες ως διαμορφωτες πυρηνικης μεταφορας και χρησεις αυτων
CY1121735T1 (el) 7-benzyλ-10-(2-meθyλobenzyλ)-2,6,7,8,9,10-eξaϋδpoϊmiδazo[1,2-α]πυριδο[4,3-d]πυριμιδιν-5(3η)-ονη για χρηση στην αγωγη του καρκινου
CY1124436T1 (el) Δικυκλικες ετεροκυκλικες ενωσεις και χρησεις αυτων στη θεραπεια
CY1122966T1 (el) 5-βρωμο-2,6-δι-(1η-πυραζολ-1-υλ)πυριμιδιν-4-αμινη για χρηση στη θεραπευτικη αγωγη καρκινου
CY1124474T1 (el) Αναλογα κομπστατινης μακρας δρασης και σχετικες συνθεσεις και μεθοδοι
CY1119058T1 (el) Ενωσεις ιμιδαζοπυρρολιδινονης
CY1121818T1 (el) Πυρρολοβενζοδιαζεπινες και συζευγματα αυτων
CY1121695T1 (el) Ενωσεις και συνθεσεις ως αναστολεις κινασης c-kit
CY1122329T1 (el) Anti-siglec-8 αντισωματα και μeθοδοι χρhσεως αυτων
CY1118860T1 (el) Νεα διαζασπειροκυκλοαλκανια και αζασπειροκυκλοαλκανια
CY1119387T1 (el) Τριαζολοπυραζινες ως αναστολεις brd4 για χρηση στην αντιμετωπιση καρκινου
CY1118250T1 (el) Ορισμενες τριαζολοπυραζινες, συνθεσεις αυτων και μεθοδοι για τη χρηση αυτων
CY1118869T1 (el) Παραγωγα αμιδο σπειροκυκλικου αμιδιου και σουλφοναμιδιου
CY1116734T1 (el) Παραγωγα κινολινης και κινοξαλινης ως αναστολεις της κινασης
CY1119619T1 (el) Παραγωγα πυριδιν-4-υλιου
UY35834A (es) Piperazinas de pirazolo sustituido como inhibidores de caseína quinasa 1 delta y epsilon